British Patient Capital
Our mission is to enable long-term investment in innovative companies across the UK led by ambitious entrepreneurs
Patient capital is crucial for growing smaller ambitious companies into world-class businesses.
The UK provides a fertile ground for innovation to thrive, but a lack of access to patient capital continues to hold back some UK companies from scaling up and fulfilling their commercial potential. British Patient Capital will enable greater availability of this type of long-term finance and will help build the UK’s innovation economy.
Key statistics
£2.5bn
investment programme
Supporting £7.5bn
of investment for British Businesses
Fixed term, evergreen and co-investment with portfolio funds
Boosting productivity through investing in growth across the UK
£2.5bn
investment programme
Supporting £7.5bn
of investment for British Businesses
Fixed term, evergreen and co-investment with portfolio funds
Boosting productivity through investing in growth across the UK
@BPatientCap
Get our latest updates from Twitter
Patient Capital Review
The government consulted on potential barriers to accessing finance and the…Read more
VC heritage
British Patient Capital builds on a successful 10-year heritage of investing £1bn into UK venture…Read more
Strategy
We focus on both fixed term and evergreen funds and will consider co-investment…Read more
Advantages
Our unique heritage enables us to target opportunities and situations where we believe…Read more
Patient Capital Review
The government consulted on potential barriers to accessing finance and the means to overcome them as part of the Patient Capital Review.
Read more
VC heritage
British Patient Capital builds on a successful 10-year heritage of investing £1bn into UK venture and growth capital.Read more
Strategy
We focus on investing in both fixed term and evergreen funds and will consider co-investment alongside our portfolio funds.
Read more
Advantages
Our unique heritage enables us to target opportunities and situations where we believe the market has missed the potential to make outsized returns.
Read more
